
Palbociclib/Letrozole Combo Boosts PFS in ER+ Advanced/Recurrent Endometrial Cancer
The combination of palbociclib (Ibrance) and letrozole (Femara) improved progression-free survival (PFS) compared with placebo plus letrozole in patients with advanced or recurrent, estrogen receptor (ER)–positive endometrial cancer, according to data from …